New Orleans, Louisiana 2021-09-14 09:42:04 –
New Orleans – From Tulane University:
Researchers at the University of Tulane School of Medicine have developed an inhaled vaccine against Klebsiella pneumoniae, a bacterium that can cause nosocomial pneumonia.According to a new study published in, the vaccine was able to protect mice from several strains of bacteria Scientific immunochemistry..
Currently, there are no FDA-approved vaccines to prevent or treat infections, and drug-resistant strains cause at least 7,900 cases and 520 deaths each year in the United States. The World Health Organization has listed these antibiotic-resistant strains on an important priority list for new treatments.
The Tulane researcher is K. The outer membrane protein X of pneumoniae was used and combined with LTA1, a vaccine adjuvant developed from E. coli bacteria, elicited an immune response. They tested the efficacy of inhaled vaccines using a mouse model in which vaccinated mice were challenged with three different strains of bacteria to determine the range of vaccine coverage.
Single-cell mRNA analysis of the mouse model shows that the CD4 + T cells induced by the inhalation vaccine are similar to those induced by the weakened whole bacterium-based vaccine that the group used in previous research studies. Was shown. Current studies have also shown that protection can be achieved independently of bacterial surface sugars and therefore may cover more bacterial strains and species compared to current pneumonia vaccines.
Among other findings, researchers have found that the vaccine provides the lungs with two different immune responses, including a population of antibody-producing B cells and IL-17-secreting T cells, also known as Th17 cells. I found.
“These T cells mechanically signal structural cells in the airways, increasing their ability to call additional white blood cells to fight infection,” said the author, who responded to the study. Dr. Jay Colts, John W Deming Internal Medicine Donated Chair.
This study lays the foundation for respiratory-targeted vaccines that induce lung T cells that are broadly protective against related Gram-negative bacteria, including many multidrug-resistant species.
“The main cause of pneumonia in the world is Streptococcus pneumoniae, and there is no reason why this technology could not theoretically be used for its pathogen,” Colts said. “I think this will open up a platform for actually rethinking how to vaccinate for respiratory infections. Perhaps most immunoprotection is needed rather than receiving intramuscular injections. Intranasal or inhaled vaccines should be given to deliver the vaccine directly to the site of infection. ”
Tulane Researchers Develop Inhaled Vaccine Against Bacterial Pneumonia Source link Tulane Researchers Develop Inhaled Vaccine Against Bacterial Pneumonia